STOCK TITAN

Wave Life Sciences Ltd. - WVE STOCK NEWS

Welcome to our dedicated news page for Wave Life Sciences Ltd. (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Sciences Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Wave Life Sciences Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Wave Life Sciences Ltd.'s position in the market.

Rhea-AI Summary
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno to participate in fireside chat at Evercore ISI HealthCONx Conference on Nov. 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
-
Rhea-AI Summary
Wave Life Sciences Ltd. (Nasdaq: WVE) announced the initiation of the RestorAATion clinical program for WVE-006, the industry’s first RNA editing clinical candidate. The program is set to investigate WVE-006 as a treatment for alpha-1 antitrypsin deficiency (AATD). Additionally, the company announced progress in their WVE-N531 and WVE-003 clinical development programs and presented preclinical proof-of-concept data for a new GalNAc-siRNA program targeting INHBE for metabolic disorders, including obesity. The company also reported cash and cash equivalents of $140 million as of September 30, 2023, with a runway expected into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.55%
Tags
earnings
-
Rhea-AI Summary
Wave Life Sciences Ltd. will host a live webcast and conference call on November 9, 2023, to review their third quarter 2023 financial results and provide business updates. Analysts can join the conference call and a recorded version will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Rhea-AI Summary
Wave Life Sciences presents preclinical proof-of-concept data for new program targeting INHBE for metabolic disorders, including obesity. INHBE loss-of-function carriers exhibit reduced waist-to-hip circumference and reduced odds ratio of Type 2 Diabetes. Reduction in INHBE of 50% or greater is expected to restore a healthy metabolic profile. Wave expects to select an INHBE clinical candidate in 4Q 2024. Wave also announces progress in siRNA and RNA editing programs. Wave expects to select five new clinical candidates by year-end 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
Rhea-AI Summary
Wave Life Sciences to present at Chardan Genetic Medicines Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
conferences
-
Rhea-AI Summary
Wave Life Sciences to participate in virtual fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences
Rhea-AI Summary
Wave Life Sciences submits first clinical trial application for WVE-006 in alpha-1 antitrypsin deficiency (AATD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
conferences clinical trial
-
Rhea-AI Summary
Wave Life Sciences Ltd. (Nasdaq: WVE) announced financial results for Q2 2023 and provided a business update, including clinical trial updates, upcoming milestones, and financial data. The company reported a net loss of $21.1 million, with $173.0 million in cash and cash equivalents as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
Wave Life Sciences Ltd.

Nasdaq:WVE

WVE Rankings

WVE Stock Data

738.60M
67.24M
18.22%
74.84%
2.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Singapore
7 Straits View

About WVE

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.